The Medicines Company Completes Acquisition of Incline

The Medicines Company Completes Acquisition of Incline Therapeutics,
PARSIPPANY, NJ and REDWOOD CITY, CA -- (Marketwire) -- 01/07/13 -- 
The Medicines Company (NASDAQ: MDCO) announced today that it has
completed its acquisition of Incline Therapeutics, Inc., a company
focused on the development of IONSYS(R) (fentanyl iontophoretic
transdermal system), a compact, disposable, needleless
Patient-Controlled Analgesia (PCA) system in development for the
short-term management of acute postoperative pain in the hospital
setting. Incline has become a wholly owned subsidiary of The
Medicines Company.  
Glenn Sblendorio, President and Chief Financial Officer said, "This
is another step to establish The Medicines Company as a leader in
acute and intensive care medicine globally. We have been very
impressed with the work that the Incline team has done with IONSYS
and look forward to collaborating with our team in Redwood City to
continue preparing the product for near-term resubmission for
marketing approval in the US and Europe." 
About The Medicines Company 
 The Medicines Company (NASDAQ: MDCO)
provides medical solutions to improve health outcomes for patients in
acute and intensive care hospitals worldwide. These solutions
comprise medicines and knowledge that directly impact the
and well being of critically ill patients. The Medicines Company's
website is 
Statements contained in this press release about The Medicines
Company that are not purely historical, and all other statements that
are not purely historical, may be deemed to be forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Without limiting
the foregoing, the words "believes," "anticipates" and "expects" and
similar expressions, including the Company's preliminary revenue
results, are intended to identify forward-looking statements. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company's actual results, levels of
activity, performance or achievements to be materially different from
those expressed or implied by these forward-looking statements.
Important factors that may cause or contribute to such differences
include the extent of the commercial success of Angiomax, the
Company's ability to develop its global operations and penetrate
foreign markets, whether the Company's products will advance in the
clinical trials process on a timely basis or at all, whether the
Company will make regulatory submissions for product candidates on a
timely basis, whether its regulatory submissions will receive
approvals from regulatory agencies on a timely basis or at all,
whether physicians, patients and other key decision makers will
accept clinical trial results, risks associated with the
establishment of international operations; the ability of the Company
to retain certain key employees of Incline; decisions of regulatory
authorities regarding marketing approval or material limitations on
the marketing of IONSYS for its current or potential new indications;
the ability of the Company to obtain marketing approvals and launch
IONSYS when planned; the extent of commercial success of IONSYS; the
ability of the Company to successfully integrate Incline's business
with the Company's other businesses and such other factors as are set
forth in the risk factors detailed from time to time in the Company's
periodic reports and registration statements filed with the
Securities and Exchange Commission including, without limitation, the
risk factors detailed in the Company's Quarterly Report on Form 10-Q
filed on November 9, 2012, which are incorporated herein by
reference. The Company specifically disclaims any obligation to
update these forward-looking statements. 
Michael Mitchell
The Medicines Company
Press spacebar to pause and continue. Press esc to stop.